{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "PRE", "regularMarketPrice": 84.6, "exchangeTimezoneShortName": "EDT", "exchangeTimezoneName": "America/New_York", "currency": "USD", "market": "us_market", "esgPopulated": false, "messageBoardId": "finmb_6966894", "gmtOffSetMilliseconds": -14400000, "shortName": "Reata Pharmaceuticals, Inc.", "longName": "Reata Pharmaceuticals, Inc.", "regularMarketChangePercent": -1.2028481, "exchange": "NGM", "regularMarketChange": -1.0299988, "regularMarketTime": 1684180805, "regularMarketDayHigh": 86.56, "regularMarketDayRange": "83.595 - 86.56", "regularMarketDayLow": 83.595, "regularMarketVolume": 634590, "regularMarketPreviousClose": 85.63, "bid": 0.0, "ask": 0.0, "bidSize": 9, "askSize": 8, "fullExchangeName": "NasdaqGM", "financialCurrency": "USD", "regularMarketOpen": 86.06, "averageDailyVolume3Month": 1524006, "averageDailyVolume10Day": 1126590, "fiftyTwoWeekLowChange": 66.13, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "fiftyTwoWeekLowChangePercent": 3.5804007, "fiftyTwoWeekRange": "18.47 - 106.69", "fiftyTwoWeekHighChange": -22.090004, "fiftyTwoWeekHighChangePercent": -0.20704849, "fiftyTwoWeekLow": 18.47, "fiftyTwoWeekHigh": 106.69, "earningsTimestamp": 1683721800, "earningsTimestampStart": 1691411400, "earningsTimestampEnd": 1691757000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -8.31, "epsForward": -4.33, "epsCurrentYear": -10.28, "priceEpsCurrentYear": -8.229572, "sharesOutstanding": 33017800, "bookValue": -1.791, "fiftyDayAverage": 93.0724, "fiftyDayAverageChange": -8.4724045, "fiftyDayAverageChangePercent": -0.091030255, "twoHundredDayAverage": 49.2671, "twoHundredDayAverageChange": 35.332897, "twoHundredDayAverageChangePercent": 0.7171702, "marketCap": 3353078528, "forwardPE": -19.538107, "priceToBook": -47.23618, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "firstTradeDateMilliseconds": 1464269400000, "priceHint": 2, "displayName": "Reata Pharmaceuticals", "symbol": "RETA"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "5320 Legacy Drive", "city": "Plano", "state": "TX", "zip": "75024", "country": "United States", "phone": "972 865 2219", "website": "https://www.reatapharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.", "fullTimeEmployees": 321, "companyOfficers": [{"maxAge": 1, "name": "Mr. J. Warren Huff", "age": 68, "title": "Chairman & CEO", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 1106699, "fmt": "1.11M", "longFmt": "1,106,699"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 9179002, "fmt": "9.18M", "longFmt": "9,179,002"}}, {"maxAge": 1, "name": "Mr. Manmeet Singh Soni", "age": 44, "title": "COO, CFO & Pres", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 1021778, "fmt": "1.02M", "longFmt": "1,021,778"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 200063, "fmt": "200.06k", "longFmt": "200,063"}}, {"maxAge": 1, "name": "Mr. Michael D. Wortley", "age": 74, "title": "Exec. VP & Chief Legal Officer", "yearBorn": 1948, "fiscalYear": 2022, "totalPay": {"raw": 773056, "fmt": "773.06k", "longFmt": "773,056"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1908116, "fmt": "1.91M", "longFmt": "1,908,116"}}, {"maxAge": 1, "name": "Dr. Colin J. Meyer M.D.", "age": 43, "title": "Exec. VP & Chief Innovation Officer", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": {"raw": 842400, "fmt": "842.4k", "longFmt": "842,400"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 5081277, "fmt": "5.08M", "longFmt": "5,081,277"}}, {"maxAge": 1, "name": "Ms. Dawn Carter Bir", "age": 51, "title": "Exec. VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 652391, "fmt": "652.39k", "longFmt": "652,391"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 3225456, "fmt": "3.23M", "longFmt": "3,225,456"}}, {"maxAge": 1, "name": "Mr. Bhaskar  Anand", "age": 44, "title": "Sr. VP & Chief Accounting Officer", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. W. Christian Wigley Ph.D.", "title": "Sr. VP & Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Dakota  Gallivan", "title": "VP & Chief Healthcare Compliance Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Steve  Harman", "title": "Sr. VP & Chief HR Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Samina  Khan M.D.", "age": 57, "title": "Chief Medical Officer & Sr. VP", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}